For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Attruby represents a significant breakthrough . These novel therapies protect https://attruby769836.slypage.com/42690860/major-attr-cm-development-the-drug-and-attruby-offer-hope